香港股市 已收市

PolyPeptide Group AG (PPGN.SW)

Swiss - Swiss 延遲價格。貨幣為 CHF。
加入追蹤清單
133.00+3.00 (+2.31%)
市場開市。 截至 11:03AM CET。

PolyPeptide Group AG

Dammstrasse 19
Zug 6300
Switzerland
41 41 723 20 34
https://www.polypeptide.com

版塊Healthcare
行業Drug Manufacturers—Specialty & Generic
全職員工1,026

高階主管

名稱標題支付行使價出生年份
Dr. Raymond De Vre Ph.D.Chief Exec. Officer1968
Mr. Jan Fuhr MillerChief Financial Officer
Mr. Daniel LasanowDirector of Global Operations
Mr. Michael StaheliHead of Investor Relations & Corp. Communications
Ms. Christina Del VecchioGen. Counsel & Corp. Sec.1978
Mr. Jan ChristensenGlobal Director of Sales & Marketing1960
截止 為止計算的金額,現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 CHF。

描述

PolyPeptide Group AG operate as a contract development and manufacturing company worldwide. It focuses on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development, and in generic products. It engages in manufacturing custom research grade peptides for use in pre-clinical and clinical development, as well as for regulatory and scientific studies; and developing neoantigen therapies as personalized immunotherapies. The company is also involved in manufacturing peptides for commercially approved peptide therapeutics; and provision of consultation services. In addition, it manufactures peptide-based generics for human and veterinary markets; and cosmetic peptides. Further, the company offers regulatory affair support services. The company was founded in 1952 and is headquartered in Zug, Switzerland.

公司管治

截至 無 止,PolyPeptide Group AG 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中:無;董事會:無;股東權利:無;現金賠償:無。

企業管治評分的資料提供: Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險,而 10 分表示較高的管治風險。